Abstract:The ever-increasing antigenic diversity of the hemagglutinin (HA) of influenza A virus (IAV) poses a significant challenge for effective vaccine development. Notably, the matrix protein 2 (M2) is a highly conserved 97 amino acid long transmembrane tetrameric protein present in the envelope of IAV. More than 99 % of IAV strains circulating in American swine herds share the identical pandemic (pdm) isoform of M2, making it an ideal target antigen for a vaccine that could elicit broadly protective immunity. Here, using soluble nanoscale membrane assemblies termed nanodiscs (NDs), we designed this membrane mimetic nanostructures displaying full-length M2 in its natural transmembrane configuration (M2ND). Intramuscular (IM) immunization of swine with M2ND mixed with conventional emulsion adjuvant elicited M2-specific IgG antibodies in the serum that recognized influenza virions and M2-specific interferon-γ secreting cells present in the blood. Intranasal (IN) immunization with M2ND adjuvanted with a mycobacterial extract elicited M2-specific IgA in mucosal secretions that also recognized IAV. Immunization with an influenza whole inactivated virus (WIV) vaccine supplemented with a concurrent IM injection of M2ND mixed with an emulsion adjuvant increased the level of protective immunity afforded by the former against a challenge with an antigenically distinct H3N2 IAV, as exhibited by an enhanced elimination of virus from the lung. The lone IM administration of the M2ND vaccine mixed with an emulsion adjuvant provided measurable protection as evidenced by a >10-fold reduction or complete elimination of the challenge virus from the lung, but it did not diminish the viral load in nasal secretions nor the extent of pneumonia that ensued after the virus challenge. In contrast, an improved formulation of the M2ND vaccine that incorporated synthetic CpG oligodeoxynucleotides (CpG-ODN) in the nanostructures administered alone, via the IN and IM routes combined, provided a significant level of protective immunity against IAV as evidenced by a decreased viral load in both the upper and lower respiratory tracts and fully eliminated the occurrence of pneumonia in 89 % of the pigs immunized with this biologic. Notably, to be effective, the M2 protein must be displayed in the ND assemblies, as shown by the observation that simply mixing M2 with empty NDs incorporating CpG-ODN (eND-CpG-ODN) did not provide protective immunity. This novel M2-based vaccine offers great promise to help increase the breadth of protection afforded by conventional WIV vaccines against the diversity of IAV in circulation and, plausibly, as a broadly protective stand-alone biologic.

A Broad Protection Provided by Matrix Protein 2 (M2) of Avian Influenza Virus

M2e-Based Universal Influenza A Vaccines

An effective vaccine against influenza A virus based on the matrix protein 2 (M2)

Immunogenicity of the M2 Protein of Avian Influenza Virus

Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine

Self-Assembly M2e-Based Peptide Nanovaccine Confers Broad Protection Against Influenza Viruses

The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines

Characterization of Immunity Induced by M2e of Influenza Virus.

Highly Conserved M2e and Hemagglutinin Epitope-Based Recombinant Proteins Induce Protection Against Influenza Virus Infection

A Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 against Both Influenza A and B

M2e-specific Antibodies Protect Against Influenza PR8 Virus in an Isotype and Route Dependent Manner.

A Universal, Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 Against Both Influenza A and B

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

Monoclonal Antibodies Recognizing EVETPIRN Epitope of Influenza A Virus M2 Protein Could Protect Mice from Lethal Influenza A Virus Challenge

An M2e-based Multiple Antigenic Peptide Vaccine Protects Mice from Lethal Challenge with Divergent H5N1 Influenza Viruses

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

N-terminus of M2 Protein Could Induce Antibodies with Inhibitory Activity Against Influenza Virus Replication

The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.

Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

Immunization with High Epitope Density of M2e Derived from 2009 Pandemic H1n1 Elicits Protective Immunity in Mice